Gene study aims to personalize breast cancer prevention drug
NCT ID NCT06062810
First seen Mar 17, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This study looks at how genetic differences in 600 people with a high-risk breast condition called LCIS affect their response and side effects from the drug raloxifene. Participants take raloxifene for at least 90 days, and researchers analyze their DNA to find gene variations linked to how well the drug works and its toxicity. The goal is to better understand who benefits most and who may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701
Rockville, Maryland, 20853, United States
Conditions
Explore the condition pages connected to this study.